Delix Therapeutics is a drug development company focusing on novel psychedelic formulations.
Delix Therapeutics
One of their main focuses is the commercialization of non-hallucinogen variation of ibogaine (tabernanthalog) as medicine for opioid use disorder and mental health treatment overall.
The company was founded by David E. Olson.
In September 2021, Delix raised U$70 million over a series A financing round. They are using the proceeds to advance two lead candidates through Phase 1 clinical trials, further expand its drug discovery platform of novel neuroplasticity-promoting compounds known as psychoplastogens, and continue to rapidly grow its world-class team.
From the website “Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature’s most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.“
News
- New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression (UC Davis, December 2020)
Activities
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Drug companies are investing big in psychedelics, but can they engineer out the trip? (Chemical & Engineering News, 06 March 2022)The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of (Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.